beta amyloid

Aducanumab (BIIB037), A selective human immunoglobulin gamma-1 (IgG1) monoclonal antibody, targets the clustered form of amyloid beta (Aβ). Aducanumab shows brain permeability and may be used to treat Alzheimer's disease (AD).

Anti-Amyloid Beta Antibody (scFv59) is a human-derived antibody produced in CHO cells that targets Amyloid-β. For isotype control, please refer to Human IgG1 kappa, Isotype Control.

Trontinemab (RG6102) is a human IgG1-κ antibody selectively targeting Aβ precursor protein (APP) with transferrin receptor p90, CD71 (TFRC), inhibits amyloid production, and can be used to study neurological disorders such as Alzheimer's disease.

Donanemab (LY3002813) is a humanized IgG1 monoclonal antibody that targets a pyroglutamate amyloid beta (Aβ) epitope at the N-terminus, showing potential for early Alzheimer's disease research [1] [2].

Solanezumab (LY 2062430) is a monoclonal antibody that binds preferentially to soluble amyloid and promotes its clearance from the brain.Solanezumab is used in the study of Alzheimer's disease.

Crenezumab (MABT 5102A) is a fully humanized anti-amyloid-beta antibody that binds to multiple forms of amyloid-beta (Aβ) for the study of Alzheimer's disease.

Lecanemab (BAN-2401) is an IgG1 monoclonal antibody targeting soluble aggregated β-amyloid (Abeta) with activity against oligomers, protofibrils, and insoluble protofibrils, and may be useful in the study of Alzheimer's disease (AD)-induced mild cognitive impairment and mild AD dementia.

Gantenerumab (R-1450) is a humanized antibody targeting amyloid-β (Aβ), used in studies of Alzheimer's disease.

Birtamimab (NEOD001) is a monoclonal antibody selectively targeting and depleting amyloid protein, used in research on light chain amyloidosis.

Oloctinebart, a humanized immunoglobulin G4-kappa (IgG4-κ) monoclonal antibody targeting LGALS3, is utilized to decrease the formation of amyloid beta oligomers [1].

Remternetug is a humanized IgG1-kappa monoclonal antibody that targets the N3pGlu peptide of the amyloid beta A4 precursor protein (APP) Aβ42. It specifically binds to the pyroglutamate-modified form of Aβ, which is implicated in the aggregation of amyloid plaques [1].